MDT

97.79

-1.28%↓

141.24

-3.25%↓

VEEV

221.27

+0.94%↑

HQY

86.08

-3.24%↓

NEOG

9.23

-2.43%↓

MDT

97.79

-1.28%↓

141.24

-3.25%↓

VEEV

221.27

+0.94%↑

HQY

86.08

-3.24%↓

NEOG

9.23

-2.43%↓

MDT

97.79

-1.28%↓

141.24

-3.25%↓

VEEV

221.27

+0.94%↑

HQY

86.08

-3.24%↓

NEOG

9.23

-2.43%↓

MDT

97.79

-1.28%↓

141.24

-3.25%↓

VEEV

221.27

+0.94%↑

HQY

86.08

-3.24%↓

NEOG

9.23

-2.43%↓

MDT

97.79

-1.28%↓

141.24

-3.25%↓

VEEV

221.27

+0.94%↑

HQY

86.08

-3.24%↓

NEOG

9.23

-2.43%↓

Kodu・Aktsiate loetelu・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Avatud

SektorTervishoid

20.78 -1.05

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

20.24

Max

21.1

Põhinäitajad
By Trading Economics
Sissetulek	11M -61M
Müük	7.9M 46M
Kasumimarginaal	-132.36
Töötajad	270
EBITDA	6.3M -58M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+82.42% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	2. märts 2026

Turustatistika
By TradingEconomics
Turukapital	672M 1.8B
Eelmine avamishind	21.83
Eelmine sulgemishind	20.78

Uudiste sentiment

By Acuity

50%

161 / 361 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

9.91 / 14.15 Toetus ja vastupanu

Syndax Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. jaan 2026, 18:44 UTC

Suurimad hinnamuutused turgudel

Agenus Falls After $141 Million Zydus Deal Closes

15. jaan 2026, 17:51 UTC

Suurimad hinnamuutused turgudel

Galaxy Digital Climbs on Texas Data-Center Expansion Approval, Tokenized CLO Issuance

15. jaan 2026, 17:25 UTC

Suurimad hinnamuutused turgudel

ASML Exceeds $500 Billion in Market Value on TSMC's Blockbuster Spending Plans -- Update

15. jaan 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. jaan 2026, 23:48 UTC

Market Talk

Nikkei May Decline as Enthusiasm Over Election Eases -- Market Talk

15. jaan 2026, 23:40 UTC

Market Talk

Gold Edges Lower Amid Abating Geopolitical Risks -- Market Talk

15. jaan 2026, 23:11 UTC

Market Talk

Global Equities Roundup: Market Talk

15. jaan 2026, 23:11 UTC

Market Talk

Ryman Healthcare's Resales Remain Key Concern -- Market Talk

15. jaan 2026, 23:01 UTC

Market Talk

New Zealand's Economy Enters An Upswing -- Market Talk

15. jaan 2026, 22:56 UTC

Market Talk

Tulu

Catalyst Metals Delivers a Beat With Record Gold Output -- Market Talk

15. jaan 2026, 22:51 UTC

Market Talk

James Hardie's Plant Closures Could Boost Profit by 2%-3% -- Market Talk

15. jaan 2026, 22:19 UTC

Omandamised, ülevõtmised, äriostud

Verizon Gets Final California Approval to Secure $9.6 Billion Frontier Deal -- WSJ

15. jaan 2026, 21:50 UTC

Market Talk

Tulu

Financial Services Roundup: Market Talk

15. jaan 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Energy & Utilities Roundup: Market Talk

15. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. jaan 2026, 21:27 UTC

Tulu

BlackRock Caps 2025 With Record $14 Trillion in Assets -- 3rd Update

15. jaan 2026, 21:15 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Global Commodities Roundup: Market Talk

15. jaan 2026, 21:11 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Global Equities Roundup: Market Talk

15. jaan 2026, 21:11 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Canada Antitrust Watchdog Confirms Review of Canadian Energy Deal -- Market Talk

15. jaan 2026, 20:10 UTC

Market Talk

U.S. Natural Gas Futures Settle Mixed -- Market Talk

15. jaan 2026, 20:04 UTC

Tulu

These Stocks Are Today's Movers: TSMC, ASML, Goldman, Morgan Stanley, BlackRock, Coinbase, Sandisk, and More -- Barrons.com

15. jaan 2026, 20:03 UTC

Market Talk

Oil Futures Fall As Iran Risk Premium Fades -- Market Talk

15. jaan 2026, 19:26 UTC

Market Talk

Silver Closes at Fresh High -- Market Talk

15. jaan 2026, 18:29 UTC

Suurimad hinnamuutused turgudel

Agenus Falls After $141M Zydus Deal Closes

15. jaan 2026, 18:20 UTC

Tulu

Wall Street Powers Nation's Biggest Banks to Record Year -- WSJ

15. jaan 2026, 17:56 UTC

Market Talk

Tulu

U.S. Bank Results Look Encouraging for European Peers -- Market Talk

15. jaan 2026, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Auto & Transport Roundup: Market Talk

15. jaan 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

15. jaan 2026, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

15. jaan 2026, 17:02 UTC

Omandamised, ülevõtmised, äriostud

KBC Group Completes Acquisition of 98.45% Stake in 365.bank From J&T Finance Group

Võrdlus sarnastega

Hinnamuutus

Syndax Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

82.42% tõus

12 kuu keskmine prognoos

Keskmine 39.11 USD 82.42%

Kõrge 56 USD

Madal 27 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Syndax Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

Osta

Hoia

Müü

Põhineb 10 analüütiku instrumendi Syndax Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

9.91 / 14.15Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

161 / 361 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.